•  
  •  
 

Article Type

Original Study

Abstract

Objective The aim of this study was to evaluate the role of adrenomedullin (ADM) as a new marker in febrile neutropenia (FN). Background ADM has an effective role in FN episode in pediatric patients with acute lymphoblastic leukemia (ALL). Patient and methods This is a prospective study of 25 patients with ALL, recruited from the Hematology and Oncology Unit, Menoufia University Hospital, Egypt, from January to June 2016 diagnosed with ALL and suffering from FN episode. Complete blood count with differential count, C-reactive protein (CRP), ADM, Na, K, Ca, creatinine, and serum glutamate-pyruvate transaminase level were evaluated on the first and fifth days of FN. Results ADM level was higher on the fifth day than on the first day of FN. It showed higher sensitivity and specificity compared with CRP and has greater area under the curve compared with CRP, with a cutoff of point 6 for CRP and 50 for ADM. CRP level was higher on the first than on the fifth day of FN. Conclusion ADM was higher on the fifth day than on first day of FN episode and has higher sensitivity and specificity compared with CRP and has greater area under the curve. Therefore, it can be considered as a new diagnostic marker in FN episode in patients with ALL. Nevertheless, CRP is still an effective cheap marker that should be used in FN episode.

Download

Share

COinS